COMMUNIQUÉS West-GlobeNewswire

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
19/03/2024
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for [...]
Cingulate to Participate in Benzinga All Live Access Event
19/03/2024
KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and [...]
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19/03/2024
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing Phase 2 study in [...]
Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024
19/03/2024
Company to give technical presentation on its innovative Growth Direct® Rapid Sterility Application LOWELL, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an [...]
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
19/03/2024
-- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner following full [...]
Tempest Reports Year End 2023 Financial Results and Provides Business Update
19/03/2024
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of care Reported new biomarker data in two important [...]
Safety Shot Wins Lawsuit Against Capybara Research and Igor Appelboom – Benzinga Retracts Defamatory Story
19/03/2024
The Default Judgment marks a significant victory in Safety Shot’s legal battle with Capybara Research and Igor Appelboom and Complete Vindication for the Company. JUPITER, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Safety [...]
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
19/03/2024
WINNIPEG, Manitoba, March 19, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of [...]
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
19/03/2024
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
19/03/2024
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002) Reports an Oxygen Desaturation Index (ODI) [...]
Nyxoah Annonce que l'Étude Pivot DREAM U.S. Atteint les Critères d'Évaluation Primaires
19/03/2024
Nyxoah Annonce que l'Étude Pivot DREAM U.S. Atteint les Critères d'Évaluation Primaires Le taux de réponse à l'indice d'apnée-hypopnée (IAH) est de 63,5 % en intention de traiter (ITT) (p=0,002). Taux de réponse à l' [...]
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19/03/2024
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy [...]
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
19/03/2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., March 19, 2024 (GLOBE [...]
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
19/03/2024
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/ [...]
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
19/03/2024
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT [...]
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19/03/2024
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key [...]
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
19/03/2024
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ [...]
Longeveron Announces 1-for-10 Reverse Stock Split
19/03/2024
MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today [...]
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results
19/03/2024
Highlights of the fiscal year include: Revenue of $999.6 million, an increase of 16% compared to $861.7 million in FY23. Net income of $55.7 million, compared to net loss of $26.1 million in FY23, with non-GAAP net [...]

Pages